Hepatitis vaccines

Sina Ogholikhan, Kathleen B. Schwarz

Research output: Contribution to journalReview articlepeer-review

Abstract

Viral hepatitis is a serious health problem all over the world. However, the reduction of the morbidity and mortality due to vaccinations against hepatitis A and hepatitis B has been a major component in the overall reduction in vaccine preventable diseases. We will discuss the epidemiology, vaccine development, and post-vaccination effects of the hepatitis A and B virus. In addition, we discuss attempts to provide hepatitis D vaccine for the 350 million individuals infected with hepatitis B globally. Given the lack of a hepatitis C vaccine, the many challenges facing the production of a hepatitis C vaccine will be shown, along with current and former vaccination trials. As there is no current FDA-approved hepatitis E vaccine, we will present vaccination data that is available in the rest of the world. Finally, we will discuss the existing challenges and questions facing future endeavors for each of the hepatitis viruses, with efforts continuing to focus on dramatically reducing the morbidity and mortality associated with these serious infections of the liver.

Original languageEnglish (US)
Article number6
JournalVaccines
Volume4
Issue number1
DOIs
StatePublished - Mar 11 2016

Keywords

  • B
  • C
  • D
  • E
  • Hepatitis A
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Hepatitis vaccines'. Together they form a unique fingerprint.

Cite this